Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes
This investigational study revealed that the Rux-Dec-mBu/Cy conditioning was tolerable and reduced relapse in high-risk AML/MDS patients.
Authors
- Jingwen Tang
- Dai‐Hong Liu (ORCID: https://orcid.org/0000-0003-3334-9113)
- Rong Yang (ORCID: https://orcid.org/0000-0002-6112-3149)
- Bo Peng (ORCID: https://orcid.org/0000-0002-4154-7657)
- Haoyang Zhang (ORCID: https://orcid.org/0009-0009-1937-2369)
- Songhua Luan
- Xiangshu Jin (ORCID: https://orcid.org/0000-0002-2568-1135)
- Fei Li (ORCID: https://orcid.org/0000-0002-7765-5975)
- Lili Wang (ORCID: https://orcid.org/0000-0003-2993-2680)
- Lu Wang (ORCID: https://orcid.org/0000-0002-0073-0666)
- Kun Qian (ORCID: https://orcid.org/0000-0003-4469-3593)
- Yujun Wei (ORCID: https://orcid.org/0000-0001-5587-2680)
- Liping Dou (ORCID: https://orcid.org/0000-0001-7352-9560)
Institutions
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1586512
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- General Hospital of People’s Liberation Army
- Beijing Nova Program